Aquestive Therapeutics Faces Class Action Lawsuit Over Anaphylm Drug Approval Timeline Claims

Key Takeaways

• Class action lawsuit filed against Aquestive Therapeutics alleging misleading investor statements about Anaphylm approval timeline
• Lawsuit claims company overstated confidence in meeting January 31, 2026 PDUFA approval date without reasonable basis
• Anaphylm represents potential breakthrough as sublingual epinephrine film alternative to traditional auto-injectors for anaphylaxis treatment

---

Aquestive Therapeutics, Inc. faces a class action lawsuit alleging the company made misleading statements to investors regarding the approval timeline for its investigational anaphylaxis treatment Anaphylm (dibutepinephrine sublingual film).

Bronstein, Gewirtz & Grossman LLC filed the lawsuit claiming Aquestive management materially overstated the timeline for approval and launch of the company’s New Drug Application (NDA) for Anaphylm. The legal action specifically targets statements where company executives expressed confidence in the NDA submission and repeatedly asserted that Anaphylm would receive FDA approval by the Prescription Drug User Fee Act (PDUFA) date of January 31, 2026.

Anaphylm’s Innovative Approach to Anaphylaxis Treatment

Anaphylm represents a potentially significant advancement in emergency anaphylaxis treatment. Unlike traditional epinephrine auto-injectors such as EpiPen, Auvi-Q, and Adrenaclick that require injection, Anaphylm delivers dibutepinephrine through a sublingual film placed under the tongue. This delivery method could offer advantages including easier administration during emergency situations and reduced needle-related anxiety.

The anaphylaxis treatment market represents a substantial commercial opportunity, with millions of patients worldwide at risk of severe allergic reactions requiring emergency epinephrine treatment. Current auto-injector products dominate this market, but sublingual delivery could capture significant market share if proven safe and effective.

IntelligenceRegulatory Impact▾

NMPA, PMDA, and TGA are the agencies to watch. Regulatory relevance reads medium for emergency medicine/anaphylaxis treatment, with Anaphylm and dibutepinephrine most exposed to upcoming decisions. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Legal and Regulatory Implications

The class action lawsuit raises serious concerns about management credibility and transparency with investors. Legal experts suggest the case centers on whether Aquestive had reasonable scientific and regulatory basis for expressing confidence in meeting the January 2026 PDUFA date, or if internal data suggested potential approval delays.

Class action lawsuits in the pharmaceutical sector often emerge when companies face unexpected regulatory setbacks, clinical trial failures, or approval delays that weren’t adequately communicated to investors. The timing of this legal action suggests potential undisclosed challenges with Anaphylm’s regulatory pathway.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Market Impact and Investor Concerns

The lawsuit threatens to erode investor confidence in Aquestive Therapeutics at a critical juncture in Anaphylm’s development. Pharmaceutical companies rely heavily on investor funding to support expensive drug development programs, and legal challenges questioning management transparency can significantly impact stock performance and future financing capabilities.

For the broader anaphylaxis treatment market, any delays to Anaphylm’s approval could postpone introduction of innovative sublingual delivery technology. Patients and healthcare providers continue relying on existing auto-injector products while awaiting next-generation treatment options.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for emergency medicine/anaphylaxis treatment pricing, access, and launch sequencing.

Looking Ahead

The January 31, 2026 PDUFA date remains the official FDA target for Anaphylm approval decision. However, the class action lawsuit suggests potential complications that could impact this timeline. Investors and industry observers will closely monitor both the legal proceedings and any updates from Aquestive regarding Anaphylm’s regulatory status.

The outcome of this case could set important precedents for pharmaceutical company communications with investors regarding drug approval timelines and the level of certainty required when making public statements about regulatory prospects.

---

Frequently Asked Questions

What does this lawsuit mean for Anaphylm’s approval prospects?

The lawsuit doesn’t directly impact FDA review, but suggests potential undisclosed challenges with Anaphylm’s regulatory pathway that could affect the January 31, 2026 PDUFA approval timeline.

When will Anaphylm be available to patients?

The official FDA target date is January 31, 2026, but the class action lawsuit alleging overstated timelines suggests potential delays beyond this PDUFA date.

How does Anaphylm compare to existing anaphylaxis treatments?

Anaphylm offers sublingual film delivery under the tongue versus injectable auto-injectors like EpiPen, potentially providing easier administration and reduced needle anxiety during emergencies.

Related coverage

• TGA Australia drug approval pharmaceutical: what the regulator is
• NMPA China FDA Drug Approval: 2026 Pathways, Timelines & Impact
• Kelun-Biotech Secures New Drug Approval for SKB118: Investor and BD Guide